

Wockhardt divests its German Business

Mumbai, June 17, 2009

Pharmaceutical and biotechnology major Wockhardt Limited today announced that it has divested its German business Esparma to Mova GmbH, a subsidiary of Lindopharm GmbH, Germany. Wockhardt had acquired the Esparma business in May 2004.

Wockhardt continues to be on the growth track and this initiative is the first step towards its on-going strategy to re-structure, rationalise and optimise all of its businesses and raise fresh capital by divesting some of its smaller operations and non-core businesses. Wockhardt is re-inventing itself by taking fundamentally strong and positive steps.

About Wockhardt

Wockhardt is a technology-driven global pharmaceutical and biotechnology major with an innovative multi-disciplinary research and development programme. It has 5 research centres and 15 world-class manufacturing plants dotting various countries and continents that are compliant to international regulatory standards such as the US FDA, MHRA and other global regulatory bodies. It has end-to-end integrated capabilities for its products, starting with manufacture of the oral and sterile API's, the dosage forms and marketing through its wholly owned subsidiary in the US. Wockhardt has a global footprint including the US, UK, Ireland, France and Germany with a multi-ethnic workforce from 14 different nationalities.